Physician profile
Lily Tran
NPI 1487865523
$5,250.85
in general payments reported to CMS, 2019-2025
21 companies · $272 in 2025
The $272 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,561 · 2020: $1,650 · 2021: $345 · 2022: $237 · 2023: $106 · 2024: $79.25 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $456.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $1,053.20 | 2019-2020 | |
| Monteris Medical Corporation | $1,037.81 | 2019-2021 | |
| Ucb, INC. | $812.39 | 2019-2025 | Fintepla |
| Neuropace, INC. | $519.59 | 2020 | |
| Livanova USA, INC. | $398.40 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Greenwich Biosciences, INC. | $377.19 | 2019-2021 | |
| Medtronic USA, INC. | $167.85 | 2019 | |
| Mallinckrodt Enterprises LLC | $145.68 | 2019 | |
| Jazz Pharmaceuticals INC. | $125.03 | 2024-2025 | |
| Zogenix INC. | $121.04 | 2021 | |
| Sk Life Science, INC. | $104.11 | 2020-2021 | |
| Immedica Pharma US, INC. | $98.76 | 2023 | |
| Aquestive Therapeutics, INC. | $77.73 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $69.66 | 2022 | |
| Novartis Pharmaceuticals Corporation | $43.83 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Masimo Corporation | $28.32 | 2019 | |
| Upsher-Smith Laboratories LLC | $26.67 | 2019 | |
| Mallinckrodt Hospital Products INC. | $14.05 | 2020 | |
| Neurelis, INC. | $13.80 | 2022 | |
| Travere Therapeutics, INC. | $8.65 | 2019 | |
| Sumitomo Pharma America, INC. | $7.09 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lily Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.